Clinical trials: Platelet Aggregation Inhibitors
Drug Safety
Data-driven Quality Improvement in Primary Care - Trial
A cluster randomised controlled trial to test the effectiveness of an informatics tool, educational and financial incentives to reduce high risk prescribing of non-steroidal anti-inflammatory drugs and anti-platelet agents.
- Trial name
- DQIP (NCT01425502)
- Testing
- DQIP Intervention
- Where
- 2 sites in United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Dundee
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Acute Coronary Syndrome
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous…
- Trial name
- STOPDAPT-3 (NCT04609111)
- Testing
- No aspirin, 1-month DAPT
- Where
- Japan
- Volunteers
- 6,002 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Blood Coagulation Disorders
Dental Extractions in Patients Under Dual Antiplatelet Therapy
The purpose of this study is to compare two hemostatic agents in patients under dual antiplatelet therapy using the intraoral bleeding time after dental extractions.
- Trial name
- DUALex (NCT02918045)
- Testing
- HemCon Dental Dressing, Oxidized Cellulose Gauze
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary
Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions
The central hypothesis for this work is that platelet - leukocyte interactions play a critical role in the pathogenesis of acute ischemic events.
- Conditions
- Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
- Trial name
- NCT01241903
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Susan Smyth
OGD, Gastric Ulcer Induced by Anti-platelet Agent
Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents
OBJECTIVES: Up to 15% of patients with peptic ulcer bleeding will develop rebleeding, mainly in those with ulcers of higher-risk stigmata (i.e. Forrest class Ia to IIb).
- Conditions
- OGD, Gastric Ulcer Induced by Anti-platelet Agent, Duodenal Ulcer Induced by Anti-platelet Agent
- Trial name
- NCT02840929
- Testing
- Second-look OGD, Esomeprazole
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 2 people
- Sponsor
- The University of Hong Kong
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin).
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents
- Trial name
- CHANGE DAPT (NCT03197298)
- Testing
- Clopidogrel, Ticagrelor
- Where
- Netherlands
- Volunteers
- 2,062 people
- Sponsor
- Thorax Centrum Twente
Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation.
- Conditions
- Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease
- Trial name
- TAILOR-DAPT (NCT05732701)
- Testing
- Algorithm-guided DAPT duration, Standard-of-care DAPT duration
- Where
- 3 sites in Bosnia and Herzegovina, Italy and 1 more
- Volunteers
- 2,788 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Arterial Obstructive Diseases, Coronary Disease
Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)
The object of the study is to determine whether different doses of SCH 530348, when added to standard medical care in persons undergoing percutaneous coronary intervention, will increase the risk of bleeding.
- Trial name
- NCT00132912
- Testing
- SCH 530348
- Volunteers
- 1,030 people
- Sponsor
- Merck Sharp & Dohme LLC
Cerebral Hemorrhage
REstart or STop Antithrombotic Randomised Trial in France
RESTART- fr is a randomised controlled trial for adults surviving spontaneous intracerebral haemorrhage who had taken an antithrombotic drug (i.e.
- Trial name
- RESTART-Fr (NCT02966119)
- Testing
- Clopidogrel or Aspirin and/or Dypyridamole
- Where
- France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Lille
Coronary Artery Bypass, Antiplatelet Agents
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
The study population will include all patients undergoing elective CABG. Consent and randomization will occur before surgery. Total 500 patients undergoing elective CABG will be randomly assigned into three groups with 1:1:1…
- Trial name
- DACAB (NCT02201771)
- Testing
- Aspirin, Ticagrelor
- Where
- 6 sites in China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Myocardial Ischemia, Hemorrhage
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
A single-center, randomized trial of admitted patients with ischemic heart disease receiving percutaneous coronary intervention and stent implantation will be conducted at University Hospital of Ferrara.
- Conditions
- Myocardial Ischemia, Hemorrhage, Quality of Life, Platelet Aggregation Inhibitors
- Trial name
- BATMAN (NCT02554006)
- Testing
- good clinical practice, bundle group
- Where
- Italy
- Volunteers
- 448 people
- Sponsor
- University Hospital of Ferrara
STEMI - ST Elevation Myocardial Infarction, Stent Thrombosis
TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk
Stent thrombosis (ST) remains a critical complication following primary percutaneous coronary intervention (PPCI) in patients with ST-elevation myocardial infarction (STEMI).
- Conditions
- STEMI - ST Elevation Myocardial Infarction, Stent Thrombosis, Antiplatelet Agents
- Trial name
- TISSARA (NCT06667349)
- Testing
- Ticagrelor
- Where
- Pakistan
- Volunteers
- 1,727 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Platelet Aggregation Inhibitors
The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients
Background: Clopidogrel, an antiplatelet prodrug, is widely used for prevention of the recurrent cardiovascular events. CYP2C19 is one of the crucial enzymes for the activation of clopidogrel.
- Trial name
- NCT02711410
- Testing
- Clopidogrel
- Volunteers
- 518 people
- Sponsor
- National Cerebral and Cardiovascular Center, Japan
Coronary Artery Disease, Coronary Artery Stenosis
Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention
There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve…
- Trial name
- NHIS (NCT06281041)
- Testing
- Antiplatelet Agents
- Where
- South Korea
- Volunteers
- 4,657 people
- Sponsor
- Samsung Medical Center
Drug Interaction Potentiation, Myocardial Infarction
Drug Drug Interactions of Aspirin and P2Y12-inhibitors
Study Objective: To investigate potential drug-drug interactions (pharmacokinetics and pharmacodynamics) of morphine and antiplatelet drugs (aspirin, clopidogrel, prasugrel, ticagrelor)
- Trial name
- NCT01369186
- Testing
- Morphine
- Where
- Austria
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Hematologic Neoplasms, Thrombocytopenia
Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
Background: Antithrombotic therapy in the context of treatment related thrombocytopenia (i.e. low levels of platelets) is not uncommon.
- Conditions
- Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
- Trial name
- MATTER (NCT03288441)
- Testing
- Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug
- Where
- 21 sites in United States, Israel and 2 more
- Volunteers
- 300 people
- Sponsor
- Maastricht University Medical Center
Gastroduodenal Ulcer
Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers
Gastroduodenal ulcers are extremely common in the community today. Though much has been written and observed concerning how ulcers form, not much has been described in the human model concerning how these ulcers heal.
- Trial name
- Lesions2 (NCT00778193)
- Testing
- Naproxen, Aspirin, Celecoxib
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Research Associates of New York, LLP
Acute Coronary Syndome
Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?
Background Acute coronary syndrome (ACS) is a term representing all diseases related to reduction in blood flow to the heart characterised by clot formation over a segment of blood vessel narrowing.
- Trial name
- PLATE NOX (NCT02169596)
- Testing
- Ticagrelor, EndoPAT - endothelial assessment
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Coronary Artery Disease, Myocardial Infarction
Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications.
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Heart Disease, Vascular Disease
- Trial name
- NCT01823185
- Testing
- clopidogrel, Ticagrelor or prasugrel
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 1,500 people
- Sponsor
- Imam Abdulrahman Bin Faisal University